4 Dec 2009: SEPS Pharma receives € 1.5 Million grant to initiate clinical development of its lead programs
SEPS Pharma, a privately held biopharmaceutical company, announced today that it has been awarded a grant worth € 1.5 million by the Flemish agency for Innovation by Science and Technology (IWT).
SEPS Pharma is a product focused company, advancing a portfolio of product opportunities with a high probability of success, based on established drugs. The company develops New Chemical Entities (NCE's) and applies superior approaches to chemically modify and deliver drugs based on its LIPRODRUG technology. This approach allows SEPS Pharma to capitalize on publicly available information, thereby lowering development risk, time and cost compared to 'traditional' NCE's, while delivering products of high value in areas of unmet need.
The grant allows SEPS Pharma to accelerate the preclinical development of its pipeline and the completion of phase I for two of its lead programs. In 2009, SEPS Pharma has concluded its first in vivo studies, validating its LIPRODRUG approach. It has demonstrated in vivo that novel prodrugs of existing parent drugs can achieve the desired outcome.
The first program is the conversion of a well known drug, which is currently only commercialized as an injectable, to an oral dosage form. SEPS Pharma aims to target new indications with larger patient populations. In a second program, the company develops a long-acting formulation of an antifungal agent. The goal of this new prodrug is to improve patient compliance by lowering toxicity levels and the number of administrations, as compared to the oral parent drug.
Yves Gonnissen, CEO, said: "We are very pleased with IWT's continued support of SEPS Pharma's technology platform and product development. This grant will allow us to continue to develop improved delivery routes for blockbuster drugs on the market, which could result in considerable benefits for patients. Completion of phase I for two of the lead programs is a pivotal milestone for the further validation of the approach and will significantly impact on the future success of the company."
9 Sep 2009: Visit us at ICSE 2009, The International Contract Services Exhibition
SEPS Pharma attends ICSE 2009 in Madrid from 13 to 15 October 2009. You can visit us at stand 8A65: www.icsexpo.com 5 July 2009: SEPS Pharma strengthens management team with Jody Voorspoels Jody Voorspoels has been appointed as the new Chief Scientific Officer. He is graduated as a pharmacist and holds a Ph.D. in pharmaceutical technology from Ghent University. Dr. Voorspoels has more than 15 years experience in pharmaceutical research and development.
In 2000 he joined Tibotec, where he was responsible for early formulation of a number of new HIV compounds. In 2002 he joined Johnson & Johnson PRD (Janssen Pharmaceutica). As principal scientist he was responsible for the development of solid dosage forms. In this function he obtained two Johnson & Johnson awards, The Philip B. Hofmann Research Scientist Award and the Johnson Medal, the most prestigious award within Johnson & Johnson for his work on the formulation and spray drying technology for Intelence™, a novel NNRTI HIV drug. Dr. Voorspoels was leading an innovation team within drug product development and was member of the innovation taskforce of Janssen Pharmaceutica. He has broad experience in the formulation and process development of HIV, CNS, metabolic and oncology drugs and has developed drug delivery systems from immediate release to controlled release, for water soluble to poorly soluble drugs, liquid to solid dosage forms.
20 May 2009: SEPS Pharma secured government grant 30 June 2008: SEPS Pharma's new website online 5 May 2008: SEPS Pharma secured government grant 16-17 Apr 2008: BioMedica 2008
From 16 till 17 April 2008, SEPS Pharma will be participate in BioMedica 2008 in Maastricht, the Netherlands. BioMedica is an annual life science summit of the Meuse-Rhine triangle. 15 Apr 2008: Private placement
SEPS Pharma increases its share capital by means of a private placement. New shareholders include LRM (Investment Company for Limburg), Hasselt University and a private investor. 19 Oct 2007: Foundation
SEPS Pharma is founded by André Remans and Yves Gonnissen. |
